Alcobra Ltd. To Release Third Quarter Financial Results And Host Corporate Update Conference Call & Webcast On November 15

TEL AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the third quarter ended September 30, 2016 before the market open, and will host a corporate update conference call and webcast on Tuesday, November 15, at 8:30 am Eastern Time.
 
Conference Call & Webcast
Tuesday, Nov 15, 2016 @ 8:30 am Eastern Time
Domestic:   855-469-0611
International:   484-756-4341
Passcode:   9001229
Webcast:   http://www.alcobra-pharma.com/events.cfm
 
Replays available through November 29, 2016
Domestic:   855-859-2056
International:   404-537-3406
Passcode:   9001229

About Alcobra Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor ContactsLifeSci Advisors, LLCMichael Rice646-597-6979mrice@lifesciadvisors.comMedia InquiriesSam Brown, Inc.Mike Beyer773-463-4211mikebeyer@sambrown.comIsrael Investor Contact:Alcobra Investor RelationsDebbie Kaye+972-72 2204661debbie@alcobra-pharma.com

Primary Logo